[HTML][HTML] Nephrotoxicity in cancer treatment: An overview
MLC Santos, BB de Brito, FAF da Silva… - World journal of …, 2020 - ncbi.nlm.nih.gov
Anticancer drug nephrotoxicity is an important and increasing adverse drug event that limits
the efficacy of cancer treatment. The kidney is an important elimination pathway for many …
the efficacy of cancer treatment. The kidney is an important elimination pathway for many …
Renal complications of hematopoietic-cell transplantation
S Hingorani - New England Journal of Medicine, 2016 - Mass Medical Soc
Renal Complications of Hematopoietic-Cell Transplantation | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
[HTML][HTML] New drug toxicities in the onco-nephrology world
MA Perazella, H Izzedine - Kidney international, 2015 - Elsevier
New anticancer medications are rapidly entering the clinical arena offering patients with
previously resistant cancers the promise of more effective therapies capable of extending …
previously resistant cancers the promise of more effective therapies capable of extending …
Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies
ML Troxell, JP Higgins, N Kambham - Advances in Anatomic …, 2016 - journals.lww.com
Cancer patients experience kidney injury from multiple sources, including the tumor itself,
diagnostic procedures, hypovolemia, infection, and drug exposure, superimposed upon …
diagnostic procedures, hypovolemia, infection, and drug exposure, superimposed upon …
[HTML][HTML] Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy
O Ballo, F Eladly, S Büttner, JA Stratmann, S Rudolf… - Annals of …, 2021 - Springer
Acute kidney injury (AKI) complicates the clinical course of hospitalized patients by
increasing need for intensive care treatment and mortality. There is only little data about its …
increasing need for intensive care treatment and mortality. There is only little data about its …
[HTML][HTML] Mini-review of kidney disease following hematopoietic stem cell transplant
R Sedhom, D Sedhom, E Jaimes - Clinical Nephrology, 2018 - ncbi.nlm.nih.gov
Advancements in hematopoietic cell transplantation (HCT) have broadened indications for
its use and resulted in more long-term survivors. Stem cell transplantation is associated with …
its use and resulted in more long-term survivors. Stem cell transplantation is associated with …
[HTML][HTML] A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan±clofarabine in allogeneic stem cell …
Abstract Pretransplant conditioning with Fludarabine (Flu)-Busulfan (Bu) is safe, but
clofarabine (Clo) has improved antileukemic activity. Hypothesis: Flu+ Clo-Bu (FCB) yields …
clofarabine (Clo) has improved antileukemic activity. Hypothesis: Flu+ Clo-Bu (FCB) yields …
Acute kidney injury in cancer patients
S Liu, J Zhao, F Wang - Clinical and Experimental Nephrology, 2022 - Springer
Objective We want to know the causes of AKI in oncology patients, including disease-related
complications and the nephrotoxicity of chemotherapy drugs, in order to provide more useful …
complications and the nephrotoxicity of chemotherapy drugs, in order to provide more useful …
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update
In the era of precision medicine, there is increasing evidence that conventional cytotoxic
agents may be suitable candidates for therapeutic drug monitoring (TDM)-guided drug …
agents may be suitable candidates for therapeutic drug monitoring (TDM)-guided drug …
[HTML][HTML] Quantification of clofarabine in urine and plasma by LC-MS/MS: suitable for PK study and TDM in pediatric patients with relapsed or refractory ALL
X Zhang, X Jia, W Tong, H Chen, N Lei, G Li, J Tai… - RSC advances, 2022 - pubs.rsc.org
Clofarabine is approved for the treatment of relapsed or refractory acute lymphoblastic
leukemia (ALL) in pediatric patients aged 1 to 21 years. Its pharmacokinetic (PK) exposure is …
leukemia (ALL) in pediatric patients aged 1 to 21 years. Its pharmacokinetic (PK) exposure is …